We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Predicts Diabetes Risk in Early Pregnancy

By LabMedica International staff writers
Posted on 13 Jun 2013
Levels of a biomarker in a pregnant woman's blood can help physicians gauge her risk of developing gestational diabetes during the first trimester. More...


Gestational diabetes causes glucose levels in the bloodstream to be higher than normal and early diagnosis and treatment can help the woman manage the condition, because if left untreated there is an increased the risk of premature delivery.

Endocrinologists at Tokyo Women's Medical University (Japan) conducted a prospective cohort study of 716 pregnant women who first visited the hospital during their first trimester between 2010 and 2011. Plasma samples were obtained at the time of routine blood testing during the first trimester, at less than 14 weeks gestation. Blood glucose levels were determined.

Enzyme-linked immunosorbent assays (ELISA) were performed in duplicate to determine the levels of soluble (pro)renin receptor [s(P)RR] using commercially available kits (Immuno-Biological Laboratories Co.; Fujioka, Japan). The detection limit of the kit was 24 pg/mL, and inter- and intra-assay coefficients of variation were 7.5% and 5.5%, respectively.

Among the 716 participants, there were 44 (6.1%) women who had gestational diabetes mellitus (GDM) and 672 (93.9%) who did not. The team found that pregnant women with elevated s(P)RR levels were more likely to be diagnosed with gestational diabetes. Women who had the highest s(P)RR levels of above 34.2 ng/mL were 2.9 times more likely to develop gestational diabetes than women who had the lowest levels. All s(P)RR concentrations were above the level required for detection of 24 pg/mL and the mean s(P)RR of the entire cohort was 30.6 ± 9.5 ng/mL.

Atsuhiro Ichihara, MD, a senior author of the study said, “In addition to gestational diabetes, recent studies have found elevated s(P)RR levels are associated with the birth of larger babies and high blood pressure in late pregnancy. The evidence suggests the biomarker is important in the interaction between mother and fetus during pregnancy." The study was published on May 29, 2013, in the Journal of Clinical Endocrinology & Metabolism.

Related Links:
Tokyo Women's Medical University

Immuno-Biological Laboratories





New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Sample Transportation System
Tempus1800 Necto
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.